Page 27 - Read Online

Conroy et al. Cancer Drug Resist 2021;4:543-58 https://dx.doi.org/10.20517/cdr.2021.07 Page 5

Phase II study of Tipifarnib in squamous head and neck cancer with HRAS mutations Tipifarnib Advanced head and neck HRAS mutations NCT02383927
squamous cell cancer
RAF inhibitors
Phase I study of LXH254 in patients with advanced solid tumours harbouring MAPK pathway LXH-254 Advanced/Metastatic solid ERK pathway mutations NCT02607813
alterations Anti-PD-1 antibody tumours
Cobimetinib and HM95573 in Patients with Locally Advanced or Metastatic Solid Tumours Belvarafenib Advanced/Metastatic solid RAS or RAF mutation NCT03284502
cobimetinib tumours
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma LXH-254 Advanced/Metastatic solid KRAS or BRAF mutant NSCLC or NCT02974725
Trametinib tumours NRAS mutant melanoma
LTT462
Ribociclib
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 BGB-283 Advanced/Metastatic solid KRAS mutant NSCLC or NCT03905148
(Mirdametinib) in Participants with Advanced or Refractory Solid Tumors PD-0325901 tumours endometrial cancer
MEK inhibitors
Trametinib and HDM201 in colorectal cancer patients with RAS/RAF mutant and TP53 wild- HDM201 (MDM2 Colorectal cancer RAS mutant and TP53 wild type NCT03714958
type advanced/metastatic colorectal cancer I inhibitor)
Trametinib
Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Cobimetinib Advanced/Metastatic solid KRAS mutation NCT03600701
Non-small Cell Lung Cancer atezolizumab tumours

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) Selumetinib Advanced/Metastatic solid none NCT03745989
MK-8353 tumours
Trial of Trametinib and Ponatinib in Patients with KRAS Mutant Advanced Non-Small Cell Lung Trametinib Advanced/Metastatic solid KRAS mutation NCT03704688
Cancer ponatinib tumours
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer Trametinib Advanced pancreas cancer none NCT03825289
hydroxychloroquine
Trametinib and Docetaxel in Treating Patients with Recurrent or Stage IV KRAS Mutation Trametinib Metastatic NSCLC KRAS mutation NCT02642042
Positive Non-Small Cell Lung Cancer Docetaxel
ERK inhibitors
First-in-Human Study of KO-947 in Non-Hematological Malignancies KO-947 Advanced/Metastatic solid BRAF, KRAS, NRAS or HRAS NCT03051035
tumours mutation
A Study of LY3214996 Administered Alone or in Combination with Other Agents in Participants LY-3214996 Advanced melanoma or BRAF or NRAS mutations NCT02857270
with Advanced/Metastatic Cancer NSCLC
Adoptive Cell therapies
G12D
Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Anti-RAS G12D Advanced/Metastatic solid HLA-A11:01 RAS mutation NCT03745326
Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients mTCR tumours
G12D
Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Anti-RAS G12D Advanced/Metastatic solid HLA-A11:01 RAS mutation NCT03190941
Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients mTCR tumours
Vaccine therapy
A Study of mRNA-5671/V941 as Monotherapy and in Combination with Pembrolizumab mRNA-5671 Advanced NSCLC, non-MSI- HLA-A11:01 and/or HLA-C08:02; NCT03948763
G12C G12D G12V
(V941-001) high CRC, PDAC KRAS , KRAS , KRAS or